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Conclusion: The Sentinel™ surface imaging device is a 
reproducible and consistent system able to detect 
misalignments with accuracy. This study shows good 
agreement between the surface scanner and CBCT in patient 
positioning. The Sentinel™ surface imaging system is a good 
supplement to the CBCT system for accurate set-up for 
fractions for whole breast irradiation after conservative 
surgery. 
 
Poster Viewing : 4: Physics: Treatment planning: 
applications III  
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Purpose or Objective: Radiotherapy dose escalation using a 
simultaneous integrated boost (SIB) is predicted to improve 
local tumour control in oesophageal cancer patients (Warren 
IJROBP 2014), yet any increase in acute bone marrow toxicity 
could reduce treatment intensity, and limit any predicted 
improvement in patient outcome. In the SCOPE oesophageal 
trial, 28% of patients treated with concurrent 
cisplatin/capecitabine and 50 Gy in 25 fractions experienced 
grade ≥3 haematological toxicity (HT3+) (Crosby Lancet Oncol 
2013). Proton therapy has been shown to significantly reduce 
haematological toxicity in lung cancer patients receiving 
concurrent chemotherapy (Komaki Radiother Oncol 2011); we 
investigate the potential of bone marrow sparing with 
protons compared to photons, in radiotherapy dose 
escalation for oesophageal tumours. 
 
Material and Methods: 21 mid-oesophageal cancer patients 
with their original conformal plan (3D50) (chosen to be a 
representative subset of the SCOPE trial) were used to study 
the bone marrow dose delivered. A surrogate for bone 
marrow was created by outlining the thoracic vertebrae, 
sternum, scapulae, ribs and clavicles using the automatic 
thresholding tool in Eclipse (Varian). Additional plans were 
created retrospectively: a volumetric modulated arctherapy 
plan (VMAT50) with the same dose as 3D50. SIB plans with a 
dose prescription of 62.5 Gy to the high risk sub-region within 
the planning treatment volume were created using VMAT 
(VMAT62.5) and proton therapy plan (IMPT62.5). Bone V20 Gy 
and V10 Gy dose-metrics were recorded and compared across 
all plans using the Wilcoxon test and Holm Bonferroni 
correction for multiple testing. Parameters from 
gynaecological cancers (Bazan IJROBP 2012) were used to 
predict normal tissue complication probability (NTCP) of 
HT3+. 
 
Results: 3D50 plans show the highest NTCP and V20 values 
for each patient. There is no significant difference between 
the VMAT50 and VMAT62.5 plans, although VMAT plans may 
cause a larger bone volume to be irradiated below 10 Gy than 
3D50. IMPT62.5 showed significant sparing for both V10 and 
V20 and much reduced NTCP 
 
 
 
Conclusion: Proton therapy plans show significant dose 
sparing for bone marrow in the 10-20 Gy dose region thought 
to be correlated with toxicity. These plans are predicted to 
reduce the risk of HT3+ by ~50% compared to photon 
techniques, and could therefore improve treatment efficacy 
of concurrent chemoradiotherapy for oesophageal cancers. 
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Purpose or Objective: The aim of the study was to evaluate 
how the dosimetric benefit of intensity-modulated proton 
therapy (IMPT) translates into estimated toxicity risk 
reduction in patients with locally advanced non-small cell 
lung cancer (NSCLC). In addition, the potential to spare the 
heart with protons and photons was explored.  
 
Material and Methods: Five patients with NSCLC were 
treated with concurrent chemoradiation, using standard lung-
sparing photon volumetric-modulated arc therapy (L-VMAT) 
to 60 Gy in 25 fractions. Three additional treatment plans 
were created for each patient: heart-sparing VMAT (H-VMAT), 
worst-case robust heart-sparing IMPT (H-IMPT), and worst-
case robust lung-sparing IMPT (L-IMPT). Doses to the organs 
at risk (heart, lung) were evaluated. Resulting normal tissue 
complication probability (NTCP) values for radiation 
pneumonitis were estimated using the dose-only QUANTEC 
model and the adjusted QUANTEC model including clinical 
risk factors 1.  
 
Results: With IMPT, both H-IMPT and L-IMPT, DVH parameters 
including the mean lung dose (MLD), the lung volume 
receiving ≥20 Gy (V20L), the mean heart dose (MHD), and the 
volume of the heart receiving ≥30 Gy (V30H) were all 
between 32 – 80% lower compared with L-VMAT (Tab 1). 
Furthermore, at these considerably lower dose levels with 
protons vs photons, the amount of dose redistributed to the 
lungs when the heart was particularly spared was still lower 
with protons (H-IMPT vs L-IMPT: 65% decrease MHD, 11% 
increase MLD), compared with photons (H-VMAT vs L-VMAT: 
62% decrease MHD, 28% increase MLD). Using the dose-only 
QUANTEC model, comparing L-VMAT with L-IMPT, the lung-
dose reductions translated into a reduction in the risk of 
symptomatic radiation pneumonitis between 4.5% to 9.2% 
(average, 5.8%). However, the QUANTEC model adjusted for 
a priori clinical risk factors showed a reduction of 
symptomatic radiation pneumonitis risk in patients without 
clinical risk factors by 2.5% to 5.4% (average, 3.3%) in 
contrast to 14.2% to 26.7% (average, 18.2%) risk reduction in 
patients with the highest a priori risk (Fig 1). For identical 
DVH reductions, and assuming a threshold risk reduction of ≥ 
10% for G2-toxicity required for indicating proton therapy, an 
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actual indication for protons thus heavily rests on individual 
clinical and patient dependent a priori risk factors.  
 
 
 
 
Conclusion: These results demonstrate that the potential of 
proton therapy to reduce the risk of radiation pneumonitis 
requires considerable reduction in lung dose, but translation 
into clinical significance is heavily driven by patient and 
clinical a priori risk factors. Therefore, multivariable NTCP 
models should play a major role in identifying patients 
eligible for proton therapy. 
1 Appelt, Vogelius, Farr, Khalik, Bentzen. Towards 
individualized dose constraints: adjusting the QUANTEC 
radiation pneumonitis model for clinical risk factors. Acta 
Oncologica 2014;53:605. 
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Purpose or Objective: The purpose of this study is to provide 
a dosimetric assessment for the feasibility of delivering lung 
SBRT using an integrated three-source Co60 and Magnetic 
Resonance Imaging (MRI) Guided Radiation Therapy (MR-IGRT) 
System. 
 
Material and Methods: Ten lung patients who were 
previously treated with Linac-based SBRT were included. For 
each patient, GTV, PTV, cord, lungs, heart, esophagus, and 
ribs were delineated. All Linac-based SBRT plans were 
generated using VMAT and consist of 2-10 6MV Rapid Arcs. 
Patients received prescription doses of 48 Gy/4fx to 50 
Gy/5fx. The Linac-based plans were imported into the View 
Ray MR-IGRT system for planning. Three-source Co60 plans 
were generated using step-and-shoot IMRT and utilized Monte 
Carlo dose calculation including the magnetic field correction 
of 0.35T. The PTV coverage for both Linac-based three-
source Co60 SBRT plans were such that 95% of the PTV 
received 100% the prescription dose. Finally, Linac- and three 
source Co60 – based plans were evaluated using dose-volume 
constraints for critical structures and target conformity index 
(CI), homogeneity index (HI) for the PTV. 
 
Results: The differences between PTV HI for Linac- and 
three-source Co60 -based SBRT plans were not statistically 
significant, ranging from 1.05 to 1.15. Three patients with 
the CIs >1.2 had target volumes <20cc although the location 
of the target did not have much influence on meeting the 
criteria for the target conformity. For all patients, the 
critical structure doses, such as maximum cord dose (<26 
Gy), dose to <15 cc of the heart (28Gy<15cc), and <5cc of the 
esophagus (18.8 Gy<5cc) were satisfactory with both 
techniques. For lung, although both the dose to <1500cc 
(11.6 Gy<1500cc) and <1000cc (13.6Gy<1000cc) criteria were 
met with both techniques, on average, the lung volumes 
receiving the 11.6Gy and 13.6Gy were 59.5% and 61.28% 
higher with three-source Co60 as compared the Linac-based 
SBRT plans respectively (P<0.05). As expected, low dose 
portion of the DVH for all critical structures generally 
covered much higher percentage of the critical structure 
volumes with three-source Co60 SBRT plans as compared to 
the Linac-based SBRT plans. 
 
 
Conclusion: Overall, a three-source Co60 integrated MR-IGRT 
system produced comparable dose distributions to the ones 
obtained with the Linac-based lung SBRT. Further studies are 
needed to evaluate benefits of this novel MR-IGRT system for 
lung SBRT, especially its ability to image and plan in real 
time and online adaptive treatment delivery. 
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Purpose or Objective: To experimentally validate a 4D 
Monte Carlo (MC) simulation method to calculate the dose 
